Cem Akin MD, PhD

Cem Akin headshot
Kenneth P Mathews M.D. Legacy Professor of Allergy and Immunology
Clinical Professor of Internal Medicine, Medical School
Available to mentor
Cem Akin MD, PhD
Cem Akin headshot
Clinical Professor
  • Center Memberships
  • Recent Publications
  • Manage Your Profile

  • Center Memberships

    • Center Member
      AI and Digital Health Innovation

    Recent Publications

    See All Publications
    • Journal Article
      Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation
      Valent P, Hartmann K, Stefanzl G, Filik Y, Bauer K, Degenfeld-Schonburg L, Gleixner KV, Siebenhaar F, Niedoszytko M, Sperr WR, Aghaallaei N, Hoermann G, Sabato V, Orfao A, Arock M, Akin C. Current Allergy and Asthma Reports, 2026 Dec 1; 26 (1): DOI:10.1007/s11882-026-01257-6
      PMID: 41701410
    • Journal Article
      Mast cell activation syndrome: Global perspectives from a World Allergy Organization survey on knowledge, diagnosis, and access to care
      Giavina-Bianchi P, Giavina-Bianchi M, Morais-Almeida M, Álvarez-Twose I, Bernstein JA, Broesby-Olsen S, Castells M, Gulen T, Hartmann K, Orfao A, Pongdee T, Rama TA, Siebenhaar F, Varricchi G, Martin BL, Fiocchi A, Wong GWK, Ansotegui IJ, Akin C. World Allergy Organization Journal, 2026 Oct 1; 19 (10): DOI:10.1016/j.waojou.2026.101470
    • Journal Article
      Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years
      Akin C, Sabato V, Gotlib J, Panse J, Álvarez-Twose I, Radia DH, Livideanu CB, Jurcic J, Elberink HO, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schafhausen P, Vadas P, Bose P, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Bonadonna P, Hartmann K, Broesby-Olsen S, Mattsson M, George TI, Shomali W, Giannetti M, Siebenhaar F, Lin HM, Bidollari I, Lampson B, Hong J, Doyle A, Tashi T, Castells M. Journal of Allergy and Clinical Immunology, 2026 Aug 1; 158 (2): 421 - 431. DOI:10.1016/j.jaci.2026.04.001
      PMID: 41985569
    • Journal Article
      MPN-1139: Bezuclastinib Expanded Access Program for Patients With Systemic Mastocytosis
      Rein L, Malinowski A, Nicoloro-Santabarbara J, Jalluri R, Cable L, Bouhana K, Crow M, Exter B, Chatfield J, Martin D, Easton R, Akin C. Clinical Lymphoma Myeloma & Leukemia, 2026 Sep 1; 26: s812 DOI:10.1016/s2152-2650(26)02397-9
    • Journal Article
      MPN-1268: Expanded Results From the Phase 2 Summit Trial: Bezuclastinib in Adults With Nonadvanced Systemic Mastocytosis
      Bose P, Boggs NA, Rein L, Modena BD, Sabato V, Hartmann K, Akin C, George TI, Yi CA, Elberink HO, Radia D, Reiter A, Piris-Villaespesa M, Dybedal I, Panse J, Oh S, Vachhani P, Hunter AM, Castells M, Livideanu C, van Daele P, Kirshenbaum A, Alvarez-Twose I, Vaughn J, Taparia M, Cerquozzi S, Mital A, Hus M, Romano A, Fahrenholz JM, Lansigan F, Papayannidis C, Pomares-Marin H, Rondoni M, Ustun C, Herrscher R, Pilla A, Zhang J, Sun L, Shah N, Jolin H, Easton R, Sachs J, Siebenhaar F, DeAngelo DJ. Clinical Lymphoma Myeloma & Leukemia, 2026 Sep 1; 26: s820 - s821. DOI:10.1016/s2152-2650(26)02411-0
    • Journal Article
      POSTER: MPN-1268: Expanded Results From the Phase 2 Summit Trial: Bezuclastinib in Adults With Nonadvanced Systemic Mastocytosis
      Bose P, Boggs NA, Rein L, Modena BD, Sabato V, Hartmann K, Akin C, George TI, Yi CA, Elberink HO, Radia D, Reiter A, Piris-Villaespesa M, Dybedal I, Panse J, Oh S, Vachhani P, MHunter A, Castells M, Livideanu C, van Daele P, Kirshenbaum A, Alvarez-Twose I, Vaughn J, Taparia M, Cerquozzi S, Mital A, Hus M, Romano A, MFahrenholz J, Lansigan F, Papayannidis C, Pomares-Marin H, Rondoni M, Ustun C, Herrscher R, Pilla A, Zhang J, Sun L, Shah N, Jolin H, Easton R, Sachs J, Siebenhaar F, DeAngelo DJ. Clinical Lymphoma Myeloma & Leukemia, 2026 Sep 1; 26: s290 DOI:10.1016/s2152-2650(26)00992-4
    • Journal Article
      Psychometric evaluation of the Mastocytosis Symptom Severity Daily Diary (MS2D2) in adults with nonadvanced systemic mastocytosis (NonAdvSM)
      Marcus JC, Akin C, Zhang J, Easton R, Lim-Watson M, Siebenhaar F, Gwaltney C, Turner R. Quality of Life Research, 2026 Aug 1; 35 (8): DOI:10.1007/s11136-026-04291-z
      PMID: 42319518
    • Journal Article
      Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study
      Siebenhaar F, Broesby-Olsen S, Castells M, George TI, Livideanu CB, Álvarez-Twose I, Panse J, Barete S, Reiter A, Dybedal I, Akin C, Van Daele P, Radia DH, Cerquozzi S, Ustun C, Sabato V, Gotlib J, Rafferty M, DeAngelo DJ, Schafhausen P, Ungerstedt J, Ogbogu PU, Florell S, Wada DA, Rets A, Lin HM, Bidollari I, Hong J, Shaheen D, Lampson B, Hartmann K. Journal of the American Academy of Dermatology, 2026 Jun 1; 94 (6): 1705 - 1713. DOI:10.1016/j.jaad.2026.02.025
      PMID: 41690487

    Featured News & Stories

    blue person figure symptoms questioning and social media icons flashing moving
    Health Lab

    Have an MCAS diagnosis? Well, maybe not

    A leading MCAS expert breaks down what mast cell activation syndrome is and how people may be getting over, and mis, diagnosed.
    woman itching skin orange blue button down
    Health Lab

    A first-of-its-kind treatment for mastocytosis

    A new drug called Avapritinib achieved longterm safety approval for indolent systemic mastocytosis.